Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study

This single-arm phase II study investigated the efficacy and safety of cabozantinib combined with nivolumab in metastatic triple-negative breast cancer (mTNBC). The primary endpoint was objective response rate (ORR) by RECIST 1.1. Biopsies at baseline and after cycle 1 were analyzed for tumor-infilt...

Descripción completa

Detalles Bibliográficos
Autores principales: Barroso-Sousa, Romualdo, Keenan, Tanya E., Li, Tianyu, Tayob, Nabihah, Trippa, Lorenzo, Pastorello, Ricardo G., Richardson III, Edward T., Dillon, Deborah, Amoozgar, Zohreh, Overmoyer, Beth, Schnitt, Stuart J., Winer, Eric P., Mittendorf, Elizabeth A., Van Allen, Eliezer, Duda, Dan G., Tolaney, Sara M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387440/
https://www.ncbi.nlm.nih.gov/pubmed/34433812
http://dx.doi.org/10.1038/s41523-021-00287-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387440/
https://www.ncbi.nlm.nih.gov/pubmed/34433812
http://dx.doi.org/10.1038/s41523-021-00287-9

Ejemplares similares